Contemporary Mouse Models in Glioma Research

William H. Hicks, Cylaina E. Bird, Jeffrey I. Traylor, Diana D. Shi, Tarek Y. El Ahmadieh, Timothy E. Richardson, Samuel K. McBrayer, Kalil G. Abdullah

Research output: Contribution to journalReview articlepeer-review


Despite advances in understanding of the molecular pathogenesis of glioma, outcomes remain dismal. Developing successful treatments for glioma requires faithful in vivo disease modeling and rigorous preclinical testing. Murine models, including xenograft, syngeneic, and genetically engineered models, are used to study glioma-genesis, identify methods of tumor progression, and test novel treatment strategies. Since the discovery of highly recurrent isocitrate dehydrogenase (IDH) mutations in lower-grade gliomas, there is increasing emphasis on effective modeling of IDH mutant brain tumors. Improvements in preclinical models that capture the phenotypic and molecular heterogeneity of gliomas are critical for the development of effective new therapies. Herein, we explore the current status, advancements, and challenges with contemporary murine glioma models.

Original languageEnglish (US)
Issue number3
StatePublished - Mar 23 2021


  • genetically engineered mouse models (GEMM)
  • glioma
  • isocitrate dehydrogenase (IDH)
  • mouse model
  • patient-derived xenograft (PDX)

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Contemporary Mouse Models in Glioma Research'. Together they form a unique fingerprint.

Cite this